October 1, 2026 27 min read

Vascular Occlusion Protocol: How to Handle a Filler Emergency in Your Med Spa

Recognition, response roles, hyaluronidase readiness, escalation, documentation, follow-up, and drills — the complete pathway for the filler emergency most practices are least prepared for.

In short

A vascular occlusion protocol is the written, medical-director-approved plan a filler practice follows when filler compromises blood flow — who recognizes it, who stops the procedure, who starts the hyaluronidase pathway, who calls whom, and what gets written down. Vascular occlusion can cause tissue necrosis or blindness, reperfusion is measured in hours, not days, and any visual disturbance is an immediate emergency-services call. This guide maps every element the protocol must contain: recognition, response roles, hyaluronidase readiness, escalation and transfer, documentation, follow-up, prevention and consent, and drills.

Not medical advice. This guide is a compliance and operations reference for practice owners, injectors, and medical directors. It is not a clinical protocol, and it does not set doses, intervals, or treatment technique — any figure quoted here is context, not an instruction. Every vascular occlusion protocol requires medical-director approval: the regimen is set by your medical director from current consensus guidance and product labeling and signed before it is used on a patient. In an emergency, follow your practice's approved protocol and call emergency services (911).

What Is Vascular Occlusion?

Vascular occlusion occurs when dermal filler blocks a blood vessel, cutting off blood supply to surrounding tissue. It's one of the most serious complications in aesthetic medicine — and one of the most time-sensitive. The FDA guidance on dermal filler risks and complications underscores the importance of practitioner training and preparedness. Every med spa that performs filler treatments must have a written vascular occlusion protocol as part of their complete emergency protocol program.

The stakes are high:

  • Untreated occlusion can lead to tissue necrosis (death)
  • Periorbital occlusions can cause permanent blindness
  • The window for effective treatment is 24-72 hours — and earlier is better
  • Proper recognition and response can completely prevent permanent damage

This page owns the vascular-event pathway: recognition, the response sequence and who runs it, escalation and transfer, documentation, follow-up, and prevention. Two companion guides cover adjacent ground in more depth, and this page does not repeat them. Our hyaluronidase and emergency reversal guide covers the drug itself — stocking, storage, expiry, standing orders, and allergy screening. The med spa emergency protocol checklist covers the crash cart, staffing, and the other emergencies your program has to address. Read this one when the question is: what happens, in what order, from the first sign of blanching to the last follow-up visit?

Why Filler Vascular Events Are Time-Critical

Most aesthetic complications tolerate a short delay while they are assessed and discussed. Vascular occlusion does not. Once filler obstructs or compresses an artery, the tissue that vessel supplies starts losing oxygen, and the injury accumulates for as long as the blockage persists. The practice is not deciding whether to act; it is deciding how fast.

Time is tissue

Our emergency protocol checklist and our hyaluronidase guide frame reperfusion the same way: it is measured in hours, not days, and outcomes are best when treatment starts early. That framing should be the organizing principle of your written protocol. Every design decision — where the kit lives, whether hyaluronidase is already in the building, who is authorized to start the pathway, how the medical director is reached — is really a decision about how many minutes the practice will lose before treatment begins. Readiness has to be front-loaded: a protocol that needs someone to find a key, look up a number, or wait for a callback has a delay built into it.

The eye changes the clock entirely

Skin occlusion is time-critical. Ocular involvement is a different category of emergency. When filler reaches the arterial supply of the eye, vision can be lost very quickly, and in-office measures cannot be relied on to reverse it. That is why our checklist treats any visual symptom during or after filler as an immediate emergency-services and emergency-ophthalmology event that bypasses every other step. A vascular occlusion protocol should never ask staff to "monitor and reassess" a vision complaint.

Why this is the emergency med spas are least prepared for

Anaphylaxis has one reflexive first move — epinephrine — and most clinical staff have trained on it. Vascular occlusion asks more. Staff have to recognize a subtler pattern that evolves over time, commit to a repeated hyaluronidase pathway most injectors have only run in training, keep reassessing until perfusion is confirmed, and run escalation in parallel. It is also rare enough that kits lapse and new hires never walk the sequence. Rarity is the reason this protocol needs more rehearsal, not less.

How Common Is Vascular Occlusion?

The data varies, but published estimates suggest:

  • Overall incidence: Approximately 1 in 6,000-10,000 filler injections
  • Impending vision loss: Approximately 1 in 40,000-100,000 injections
  • Higher risk areas: Nose (glabella), nasolabial folds, lips, tear troughs

A busy injector performing 50 filler treatments per week might encounter 2-4 vascular events over a 10-year career. It's rare enough that many practitioners never see one — but common enough that every practitioner should be prepared.

Anatomy: Why It Happens

High-Risk Zones

Glabella (between eyebrows): Supratrochlear and supraorbital arteries. Direct communication with ophthalmic artery. Highest risk for vision complications.

Nose: Dorsal nasal artery (branch of ophthalmic), angular artery. Complex anastomoses make occlusion particularly dangerous.

Nasolabial folds: Angular artery, superior labial artery. Common injection site = common occlusion site.

Lips: Superior and inferior labial arteries. High blood flow, but also high occlusion potential with product migration.

Mechanism of Occlusion

  1. Direct intravascular injection: Product injected into a vessel
  2. External compression: Product volume compresses adjacent vessels
  3. Retrograde flow: Product pushes back into proximal vessels (especially concerning for vision)

What anatomy means for your written protocol

Anatomy is clinical knowledge, but it has an operational consequence. Your protocol should name the treatment areas your practice treats as higher-risk and state what changes when an injector works there. That might mean only credentialed injectors treat those zones, or the kit is physically in the room for those appointments. The technique choices themselves belong to your medical director and injectors; the protocol's job is to make sure higher-risk appointments carry higher readiness.

Recognition: The First Critical Step

Early recognition is everything. Know these signs:

Immediate Signs (During Injection)

  • Blanching: Skin turns white in a vascular pattern
  • Pain: Severe, disproportionate pain during/after injection
  • Dusky discoloration: Grayish, bluish, or mottled skin color
  • Slow capillary refill: Press skin, takes >2 seconds to pink up

Vision-Related Signs (Emergency)

  • Eye pain
  • Vision changes (blurring, field loss)
  • Pupil abnormalities
  • Eye movement changes

If ANY vision symptoms appear: This is a medical emergency requiring immediate ophthalmology consultation and likely ER evaluation.

Evolving signs: how an occlusion progresses

Recognition is a pattern, not a single sign, and the pattern changes with time. The early picture — blanching, pain out of proportion to the procedure, and a dusky or mottled discoloration — is the one described above. If an occlusion is missed or only partly reversed, our hyaluronidase guide describes how it progresses: delayed capillary refill, coolness, a net-like livedo pattern that follows the course of a vessel rather than sitting at the injection point, and later blistering. Each of these is a reason to activate, or re-activate, the protocol — not a reason to wait and see.

Staff do not need diagnostic certainty to act. The rule in the protocol should be that suspicion is enough: the injector stops, the medical director is notified, and the pathway begins. As our checklist puts it: when in doubt, treat and escalate.

The visual-disturbance red flag

Of everything on this page, this is the line every staff member must know without looking it up. Any visual change during or after a filler treatment — blurring, loss of part of the visual field, eye pain, an abnormal pupil, or a change in eye movement — is an emergency. So is a severe headache or any neurologic symptom such as facial drooping, weakness, or difficulty speaking. Our emergency protocol checklist lists any vision symptom during or after filler injection among its 911 criteria, and its escalation ladder sends vision symptoms to emergency ophthalmology and the emergency department in parallel.

Write this into the protocol as an override. A visual symptom removes every other step as a precondition: staff call 911 and the medical director at the same time, the patient is not sent home or told to see how it goes, and the practice's pre-identified ophthalmology pathway is activated. It belongs on the quick-reference card, in every drill, and in written aftercare.

Delayed presentation: when the patient has already left

Some occlusions are noticed later, by the patient at home, as increasing pain or a spreading color change. Your protocol therefore has to reach beyond the treatment room. Aftercare instructions should tell every filler patient which symptoms to report and how to reach the practice urgently, with an explicit instruction to call 911 for any change in vision. Front-desk staff need a triage script for those calls: a patient describing a color change or new pain after filler is routed to a clinician immediately, not booked into the next open appointment.

WRITTEN, SIGNED, REHEARSED

Turn this pathway into a signed protocol.

The Emergency Protocols Kit includes the Vascular Occlusion Protocol — recognition criteria, response roles, escalation, and documentation forms — alongside anaphylaxis and the other emergency SOPs, ready for your medical director to adapt, sign, and date.

View Emergency Protocols Kit — $297
Instant download · 30-day guarantee · Medical Director Ready

Injecting filler every day? The Injectables Protocol Kit adds hyaluronidase dosing and stocking SOPs and dissolving consent forms.

The Vascular Occlusion Response Protocol

Immediate Response (0-15 minutes)

  1. Stop injection immediately — Do not inject more product. Remove needle/cannula.
  2. Assess and document — Note exact location and extent of blanching. Time of onset. Photograph immediately.
  3. Apply warm compress — Warm (not hot) compress to affected area. Promotes vasodilation. Do NOT use ice.
  4. Administer hyaluronidase (for HA fillers) — Reconstitute if needed. Inject into and around affected area. Typical dose: 150-300 units initially, may repeat. Massage to disperse.
  5. Consider aspirin — 325mg aspirin (if no contraindications). Discuss with Medical Director.
  6. Massage — Gentle massage to affected area to help disperse product.
  7. Nitroglycerin paste (if available) — Topical application promotes vasodilation. Medical Director approval required.

Follow-Up Response

First 24 hours: Monitor patient closely, may need repeat hyaluronidase, contact Medical Director, specialist consultation if not improving.

Days 2-7: Daily assessment (in-person preferred), photo documentation, wound care if tissue damage.

Staff roles: who does what during the event

What turns the sequence above into a working protocol is assigning every step to a named role before the event. Our emergency protocol checklist sets out four roles for any emergency — who calls 911, who documents, who meets EMS, and who stays with the patient. A vascular occlusion protocol adds the clinical roles specific to a filler event:

  • The treating injector — stops the procedure the moment occlusion is suspected, tells the team exactly what was injected, where, and how much, and starts the pathway the standing order authorizes.
  • The prescriber or medical director — owns the decisions that constitute practicing medicine: hyaluronidase dosing for a suspected occlusion, any supportive medication, and the call on whether to transfer. The protocol must state how this person is reached within minutes, and who acts if they are not immediately reachable.
  • The kit runner — brings the emergency kit and the signed dosing reference to the room and confirms the hyaluronidase on hand is in date.
  • The documenter — starts a timeline with clock times the moment the event begins, rather than reconstructing it afterward from memory.
  • The 911 caller — activates emergency services when the protocol's threshold is met, gives the address, stays on the line, and does not also provide hands-on care.
  • The EMS liaison — clears the route from the door, has the chart and product information ready, and brings paramedics straight to the patient.
  • The patient companion — stays with the patient continuously, keeps them informed and calm, and reports any change, especially in vision.

In a small practice one person will hold several roles; the protocol should say which combine when few staff are on shift, and never leave a role unassigned.

Hyaluronidase: Your Most Important Tool

For hyaluronic acid fillers, hyaluronidase (FDA-approved enzyme for HA filler dissolution) is the antidote. Every practice performing HA filler injections should have it on hand.

Key points:

  • Initial dose: 150-300 units injected into and around affected area
  • May repeat: Every 30-60 minutes if not improving
  • Distribution: Multiple small injections, massage to distribute

Per published guideline on managing filler-induced vascular occlusion, high-dose hyaluronidase administered promptly is the standard of care for HA-related vascular occlusions.

For non-HA fillers (Radiesse, Sculptra, Bellafill): Hyaluronidase will NOT dissolve these products. Focus on supportive care and lower threshold for specialist referral.

Availability is a practice obligation, not an injector's choice

Whether hyaluronidase is in the building should never be left to individual injectors. Our hyaluronidase and emergency reversal guide sets out why on-site availability has become the expectation for any practice placing HA filler: in date, in the quantity your adopted protocol requires, stored correctly, with a signed dosing protocol and a standing order behind it. The vascular occlusion protocol should point to that stock directly — where it lives, who checks it, and the minimum quantity your medical director has set — rather than restating the stocking rules. If the shelf is below the minimum, filler appointments do not go ahead.

The treating practitioner's responsibility

The injector who placed the filler owns the first minutes of the response — and needs to know the limits of their authority. Our emergency checklist treats hyaluronidase dosing for a suspected occlusion as a prescribing decision for the prescriber or medical director, while our hyaluronidase guide explains how a signed standing order lets a nurse begin administration without waiting for a fresh order each time. Which of those applies in your practice depends on your state's delegation rules and on what your standing order actually says — and your written protocol has to settle it, by name, before the emergency.

The regimen itself — the amount, how it is distributed, how often perfusion is reassessed, and what end point stops treatment — is set by your medical director from current consensus guidance and product labeling and written into the signed protocol. Where this page quotes a figure, treat it as context for why stock levels matter, not as an instruction. In a true occlusion emergency, our hyaluronidase guide notes that treatment is not delayed for allergy testing; anaphylaxis readiness — epinephrine, antihistamines, and injectable hydrocortisone — is kept on hand instead.

Non-HA products need their own branch

Because hyaluronidase does nothing for biostimulatory or permanent fillers, the protocol needs a separate branch for a suspected occlusion involving a non-HA product: immediate medical director involvement, supportive care as they direct, and an earlier move to specialist referral. That branch only works if the chart records exactly which product, lot, and volume were placed — which is why product documentation is a safety control, not paperwork.

When to Escalate

  • Medical Director: Any suspected vascular occlusion — immediately
  • Ophthalmology (Emergency): ANY vision symptoms, periorbital or glabellar occlusion
  • Emergency Department: Vision involvement, systemic symptoms, patient instability
  • Plastic/Vascular Surgery: Extensive tissue compromise, necrosis developing

Our emergency protocol checklist treats this as a ladder rather than a single "call the doctor" step. The medical director is notified immediately for any suspected occlusion. Any vision symptom goes to emergency ophthalmology and the emergency department in parallel. Systemic symptoms or an unstable patient go to the emergency department. Extensive compromise or developing necrosis despite hyaluronidase goes to plastic or vascular surgery. Continued in-office management is reserved for cases where the medical director confirms improving perfusion with no vision or systemic involvement.

Pre-arranged escalation contacts

Escalation most often fails because the number is not at hand. The protocol should list, on the same card as the response sequence, the medical director's direct line and a named backup prescriber, the nearest emergency department, the ophthalmology referral pathway your practice has identified in advance, and a plastic or vascular surgery contact. Confirm those contacts before you need them. An ophthalmology practice that does not accept urgent referrals from an aesthetic clinic is not a pathway, and the time to discover that is not during the event.

The emergency transfer handoff

When a patient is transferred, the receiving clinicians need information the practice already has. The EMS liaison should hand over the product injected, its lot number and volume, the treatment areas, the time of injection and the time symptoms were recognized, everything given in response and when, and the medical director's contact details. Sending product information with the patient spares the receiving team from guessing whether hyaluronidase is even relevant. A one-page transfer sheet, pre-formatted and kept in the kit, turns this into a fill-in-the-blanks task rather than a scramble at the door.

When the medical director cannot be reached

"Immediately reachable" is a real supervision standard in several states, and an unanswered phone during an adverse event becomes part of the record. Your protocol must name the backup prescriber, say when staff move on to them, and state what the team may do meanwhile under the standing order. It must also say that a vision symptom or an unstable patient never waits for either call — 911 comes first. Supervision rules differ by state; check yours on our med spa regulations by state hub before you write the backup chain.

Documentation During and After the Event

Documentation is the part of the protocol that protects the patient's continuity of care and the practice's defensibility once the patient is safe — and it starts in the first minute, not after the event is over.

The live timeline

The documenter keeps a running record with clock times rather than durations: injection, first sign and who noticed it, when the medical director was called and answered, each hyaluronidase administration with its time and the amount given, each reassessment and what it showed, when 911 was called, when EMS arrived, and when the patient left the building. Timestamped photographs at onset and at each reassessment belong in the same record.

The incident record

The post-event standard in our checklist applies directly: write it the same day, as a single record a board, an insurer, or a plaintiff's attorney could be handed without anyone reconstructing it. For a vascular event it should include the product, lot, volume, and treatment area; the presenting signs; every treatment given and by whom; the escalation decisions and their times; the follow-up plan; the names and roles of everyone present; and a root-cause review with the corrective action taken. Our guide to emergency protocols and lawsuit exposure explains why.

Follow-Up After a Vascular Event

A vascular occlusion does not end when the patient leaves the building. The follow-up response above describes close monitoring in the first day and daily assessment through the first week, consistent with the daily in-person assessment for the first week that our checklist describes. The exact schedule, and what triggers a return to more intensive treatment, should be written into the signed protocol by your medical director.

What each follow-up contact records

Each follow-up should record standardized photographs taken with the same lighting and angle as the onset photos, the reassessment findings, any further treatment, the symptoms the patient reports, and the plan until the next contact. Consistency is the point: a recovery visible across matched photographs is evidence of a monitored, managed event; a series of inconsistent phone snapshots is not.

Wound care, specialist referral, and the long tail

If tissue damage develops, the medical director decides on wound care and specialist referral; the protocol should name those pathways in advance and require every referral and its outcome to be charted. The protocol should also assign a named staff member to confirm each scheduled contact actually happens.

The after-action review

Once the patient is stable, review the event like a drill — where minutes were lost, whether the kit and contacts worked, what will change — and route any amendment through the medical director for signature. An event that changes nothing in the protocol is usually an event nobody reviewed.

Prevention: The Best Protocol

Prevention starts with ensuring only qualified injectors perform filler treatments under proper medical supervision in Florida.

For a complete, compliant protocol you can implement immediately, see our Emergency Protocol Kit.

  • Know the anatomy: High-risk zones require extra caution
  • Slow injection: Inject slowly with minimal pressure
  • Small aliquots: Never bolus large amounts
  • Aspiration: Aspiration before injection adds a safety check
  • Cannulas: May reduce risk in some areas
  • Staged treatments: Less product per session reduces risk

Anatomy awareness and injector competency

The strongest prevention control an operator has is deciding who may inject where. Credentialing should confirm each injector's training in facial vascular anatomy and in the practice's occlusion protocol before they treat higher-risk areas, and competency should be rechecked as part of the practice's regular training cycle. Supervision should match the risk: a newly hired injector's first glabellar or nasal treatments should not be scheduled on a day the medical director is unreachable. Who may inject at all is a state-law question — see our guide to who can inject across the United States.

Technique choices belong in the clinical protocol

The technique measures listed above — injection speed and pressure, small aliquots, aspiration, cannula use, and staging — are clinical choices your injectors make within standards your medical director sets. The operator's role is to make sure those standards are written down, known by every injector, and reflected in the chart for each treatment: product, volume, treatment areas, and needle or cannula.

Informed consent disclosure

Filler consent should name vascular occlusion specifically and in plain language, along with its possible consequences: skin injury and scarring from tissue necrosis and, rarely, permanent vision loss or blindness. It should explain that the practice has an emergency protocol, that hyaluronidase may be used to treat an occlusion caused by HA filler and that non-HA products cannot be dissolved, and that the patient may be transferred to emergency care. Generic "risks include bruising and swelling" language does not meet that bar. Our lip filler safety and consent guide and med spa consent forms guide cover how risk-specific consent should be structured.

Emergency-Kit Readiness and Drills

A vascular occlusion protocol is only as good as the kit and the rehearsal behind it. Our emergency protocol checklist covers the full crash cart; the points below are the ones specific to the vascular pathway.

What the vascular occlusion kit needs

  • Hyaluronidase in the quantity your signed high-dose occlusion protocol requires, in date, and stored according to its labeling
  • Reconstitution and administration supplies as your protocol specifies
  • Supportive items your protocol names — our checklist lists a warm compress, aspirin, and nitroglycerin paste for vascular occlusion, each used only as your medical director directs
  • Anaphylaxis management — epinephrine, antihistamines, and injectable hydrocortisone (see our anaphylaxis protocol guide)
  • The signed dosing reference and the standing order, physically in the kit, not only on a shared drive
  • A laminated quick-reference card — recognition signs, the visual-disturbance override, role assignments, and escalation contacts
  • Pre-formatted timeline and transfer sheets so documentation and handoff start without hesitation

Expiry is the classic failure. Our checklist and our hyaluronidase guide both call for checking the kit monthly and logging the check with a signature, and both name hyaluronidase and epinephrine as the items most often found expired.

Drills that test the real sequence

Our checklist recommends quarterly drills if your practice injects hyaluronic acid filler, because vascular occlusion is the scenario where minutes matter most and hesitation costs the most. A useful drill is not a discussion. Staff physically retrieve the kit, open it, find the hyaluronidase and confirm its date, locate the dosing reference, call out the role assignments, place a practice call to the medical director, and walk the escalation ladder — including the visual-disturbance branch and the transfer handoff. Run some unannounced, on a day your most experienced nurse is off.

Record each drill: the date, the scenario, who took part, what went wrong, and what changed as a result. Those records are what show an inspector that the protocol is alive rather than decorative.

What Must a Vascular Occlusion Protocol Include?

A vascular occlusion protocol must turn a rare, time-critical emergency into a rehearsed sequence: how staff recognize it, who does what, how hyaluronidase is authorized and stocked, when the patient is escalated or transferred, how the event is documented and followed up, and how the protocol is drilled, signed, and reviewed by the medical director.

Use the list below to check your own protocol. Each item is covered in a section above.

  1. Scope and trigger. What it covers, and the rule that suspicion alone activates it.
  2. Recognition criteria. Early and evolving signs in plain language, with visual disturbance and neurologic symptoms written as an override.
  3. The response sequence. Stop, notify, begin the hyaluronidase pathway for HA filler, supportive measures as directed, reassess, escalate — plus a separate branch for non-HA products.
  4. Named roles. Every role above assigned in advance, including combinations for a small team.
  5. Authorization. The standing order, who may administer hyaluronidase under it in your state, and who makes the dosing decision.
  6. The dosing reference. The regimen your medical director has adopted from current consensus guidance and product labeling, signed and dated — see our hyaluronidase guide for what that document must cover.
  7. Stock and kit. The minimum hyaluronidase quantity, the kit contents and location, and the logged expiry check.
  8. Escalation ladder and contacts. Medical director and backup, 911, the emergency department, ophthalmology, and surgical referral.
  9. Transfer handoff. What goes with the patient, on a pre-formatted sheet.
  10. Documentation. The live timeline, timestamped photographs, and a same-day incident record.
  11. Follow-up. A schedule set by the medical director, matched photographs, referral tracking, and an after-action review.
  12. Prevention and consent. Higher-risk zone readiness, injector credentialing, product records, and risk-specific consent.
  13. Training and drills. How often the team drills, the scenarios covered, and the attendance records.
  14. Approval and review. The medical director's signature, a version date, and a standing review date — brought forward after any event or any change in the products you stock.

Can You Use a Vascular Occlusion Protocol PDF?

Yes, as a starting point — but a vascular occlusion protocol PDF is not your protocol until it has been adapted to your practice, your products, and your escalation contacts, and approved and signed by your medical director. A template supplies the structure. Only the practice can supply the specifics that make it usable in the first minutes of an emergency.

The gaps in downloaded templates are predictable. A template may quote a dosing regimen your medical director has not adopted or that does not fit the hyaluronidase product you stock. It may assume a staffing model, or another state's delegation rules, that you do not have. And it will never contain your escalation contacts or your ophthalmology pathway — exactly the details staff reach for first.

Treat the review as a line-by-line exercise: every product name, contact, role, and authorization checked against what is really in your building, then signed and dated. The document that protects your patients and your practice is the signed, practice-specific version, not the download. Our Emergency Protocols Kit is built for that workflow, with bracketed fields for your medical director, practice details, and review dates.

Key Takeaways

  1. Time is tissue — Early recognition and treatment save outcomes
  2. Hyaluronidase is essential — Stock it, know how to use it
  3. When in doubt, treat — Better to give hyaluronidase unnecessarily than to wait too long
  4. Vision symptoms = emergency — Immediate ophthalmology and ER
  5. Document everything — Protects everyone
  6. Practice before you need it — Mock drills save real patients

Get the Free Med Spa Compliance Checklist

The full practice-readiness audit — the yes/no checkpoints behind this guide, delivered to your inbox so you can find your gaps before a board does.

No spam. Unsubscribe anytime.

Last reviewed October 1, 2026. Content is reviewed whenever federal or state regulations change. Written for licensed med spa operators and medical directors.

Disclaimer: This article is for educational and compliance-planning purposes only and is not medical, legal, or regulatory advice. It does not describe injection technique or specific dosing and is not a substitute for clinical training. Any vascular occlusion protocol, including hyaluronidase dosing and supportive measures, must be written, approved, and signed by your medical director from current consensus guidance and product labeling. In an emergency, follow your practice's approved protocol and call emergency services. Verify the rules that apply in your state before relying on any statement here.

Frequently Asked Questions

Common questions about vascular occlusion and building a vascular occlusion protocol.

What is vascular occlusion in aesthetic medicine? + −
Vascular occlusion occurs when dermal filler blocks blood flow to or through a vessel, causing tissue ischemia. It can result from direct intravascular injection, external compression, or retrograde embolism. Without immediate treatment, the tissue can progress to permanent necrosis, scarring, or — in the most serious cases — blindness.
How quickly does vascular occlusion need to be treated? + −
Treatment within 0–4 hours offers the best chance of full tissue recovery. After 8 hours, significant permanent damage is likely. After 24+ hours, necrosis is probable. Vision-related symptoms from intravascular injection can cause permanent blindness within minutes — always treat vision symptoms as an immediate emergency requiring 911 activation.
What are the signs of vascular occlusion after filler injection? + −
Immediate signs include blanching (sudden white or pale skin appearance), severe pain disproportionate to the procedure, and dusky or mottled (blue/purple) skin discoloration. Vision changes, facial drooping, or any neurological symptoms indicate a more serious embolic event requiring immediate 911 activation and emergency ophthalmology consultation.
What is hyaluronidase and why do med spas need to stock it? + −
Hyaluronidase is an enzyme that dissolves hyaluronic acid fillers. For vascular occlusion, it is injected at high doses (150–1,500 units depending on severity) into the affected area to rapidly dissolve the obstructing filler and restore blood flow. Any med spa that injects HA fillers must stock hyaluronidase on-premises at all times — this is a non-negotiable safety requirement.
Which injection sites carry the highest risk of vascular occlusion? + −
The glabella (between eyebrows) and nasal dorsum/tip carry the highest risk because these areas have direct anastomotic connections to the ophthalmic artery, which supplies blood to the eye. The nasolabial folds, lips, and temples also carry high risk. Injectors must have thorough knowledge of facial vascular anatomy before performing filler treatments.
What is a vascular occlusion protocol? + −
A vascular occlusion protocol is a written, medical-director-approved plan that tells a filler practice exactly what to do when filler compromises blood flow: how staff recognize the signs, who stops the procedure and who calls whom, how hyaluronidase is authorized and given for hyaluronic acid filler, when the patient is escalated to emergency care or ophthalmology, and how the event is documented and followed up.
What should a vascular occlusion protocol include? + −
At minimum: the trigger that activates it, recognition criteria with a visual-disturbance override, the response sequence with a separate branch for non-HA fillers, named staff roles, the standing order and who may administer hyaluronidase, a signed dosing reference set by the medical director from current consensus guidance and product labeling, kit contents and expiry checks, the escalation ladder and contacts, a transfer handoff, documentation and follow-up requirements, prevention and consent standards, a drill schedule, and the medical director's signature with a version and review date.
Can I use a vascular occlusion protocol PDF template? + −
As a starting point, yes. A template must be adapted to your practice, to the filler and hyaluronidase products you actually stock, to your staffing and your state's delegation rules, and to your own escalation contacts, then reviewed line by line and signed by your medical director before it is used. An unadapted download, especially one quoting a dosing regimen your medical director has not adopted, is a liability rather than a protocol.
What should staff do if a filler patient reports a vision change? + −
Treat it as an emergency immediately. Any visual change during or after filler, such as blurring, loss of part of the visual field, eye pain, or pupil or eye-movement changes, means calling 911 and the medical director at the same time and activating the practice's emergency ophthalmology pathway. It is never a monitor-and-reassess situation, and the patient should not be sent home. Follow your practice's approved protocol and the direction of emergency services.
How often should a med spa drill its vascular occlusion protocol? + −
Our emergency protocol checklist recommends quarterly drills for practices that inject hyaluronic acid filler, because vascular occlusion is the emergency where hesitation costs the most. Drills should be hands-on, from retrieving the kit to walking the escalation ladder, and each one should be recorded with its date, scenario, and attendees.

Related Articles

Get a Complete Vascular Occlusion Protocol

Our Emergency Bundle includes a detailed, step-by-step Vascular Occlusion Protocol with hyaluronidase dosing tables, documentation forms, and quick-reference cards.

Get the Emergency Bundle — $297
30-Day Money-Back Guarantee